{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-011953","form_type":"8-K","ticker":"RVPH","cik":"0001742927","company_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","filed_at":"2024-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.848384+00:00","generated_at":"2026-06-03T22:58:18.930957+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Reviva FY2023 net loss $39.3M; restates 2022; positive Phase 3 schizophrenia data; RECOVER-2 trial planned","bullets":["Net loss $39.3M ($1.65/sh) for FY2023 vs restated $28.3M ($1.45/sh) for FY2022.","Cash $23.4M as of Dec 31, 2023; completed $30M registered direct offering in Nov 2023.","Restated FY2022 results due to ~$3.9M under-accrual of clinical trial expenses.","Phase 3 RECOVER-1 met primary endpoint: 10.1-point PANSS reduction at 50mg vs placebo (p<0.001).","Registrational RECOVER-2 trial starts Q2 2024; NDA submission for brilaroxazine targeted Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-011953","json":"https://secwatch.observer/filing/0001437749-24-011953.json","markdown":"https://secwatch.observer/filing/0001437749-24-011953.md","text":"https://secwatch.observer/filing/0001437749-24-011953.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924011953/0001437749-24-011953-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924011953/rvph20240325_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:58:18.930957+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f3d8f784c4b603b5912dbd8ae0a34ceb9c7c457","claim":"REVIVA PHARMACEUTICALS HOLDINGS, INC. reported the full year ended December 31, 2023 results: net income approximately $39.3 million, EPS $1.65 per share.","evidence_excerpt":"For the year ended December 31, 2023, net loss was approximately $39.3 million, or $1.65 per share, compared to approximately $28.3 million, or $1.45 per share, for the year ended December 31, 2022 (as restated).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1742927/000143774924011953/0001437749-24-011953-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Net income","value":"approximately $39.3 million"},{"label":"EPS","value":"$1.65 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}